In recent years, studies [10, 11] have found that SGLT2 inhibitors not only improve blood glucose and reduce blood lipid, body weight, and blood pressure in patients with type 2 diabetes (T2DM) but also have a protective effect on the cardiovascular system. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.